Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Oxfendazole in Healthy Volunteers
NCT03035760Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxfendazole in helminthic infection (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Number of Subjects Reporting Adverse Events Related to Oxfendazole. Started May 2017; status: completed.
02
Drugs
oxfendazole
03
Conditions
helminthic infection
Beyond the preview
Go deeper on NCT03035760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035760.